Annovis Bio (ANVS) announced new results that demonstrate buntanetap’s ability to attenuate inflammation and improve cellular health in Alzheimer’s patients, suggesting potential disease-modifying effects beyond symptomatic relief. The analysis of patient samples from the Phase 2/3 AD study revealed that buntanetap targets key biomarkers of neuroinflammation and neurodegeneration. The following inflammatory markers were reduced in the treatment group vs placebo: IL-5, IL-6, S100A12, IFN-gamma, and IGF1R. These molecules are known to drive pro-inflammatory responses in AD and have been associated with elevated amyloid-beta burden. By modulating these pathways, buntanetap may reduce chronic inflammation and attenuate amyloid accumulation. Equally compelling was the observation that buntanetap decreased levels of NFL, a protein fragment released from damaged neurons, indicating improved cellular integrity and neuronal health. Notably, these responses were observed in all patients with positive pTau217 plasma levels, including those with mild and moderate stages of the disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio appoints Guerin as Chief Financial Officer
- Annovis Bio announces publication of new article in Biomolecules on buntanetap
- Annovis Bio’s Promising Alzheimer’s Study: What Investors Need to Know
- Annovis Bio price target lowered to $10 from $12 at H.C. Wainwright
- Annovis Bio Reports Q2 2025 Progress and Financials